Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Johnson & Johnson(JNJ-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low235.43
Day High240.79
Open:238.12
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Johnson & Johnson

Select a category then submit the form to load news
Stock Target Advisor
Investors Flee Risk on Macro Data and Energy Fears: Market Analysis for March 6th, 2026
Market Analysis for March 6th, 2026
Newswire.ca
CANADA-WIDE TALCUM POWDER CLASS ACTION CERTIFIED AGAINST JOHNSON & JOHNSON
Tipranks
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
Zacks Investment Research
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
Stock Target Advisor
Oil Price Surge Sinks Stocks-Market Analysis for March 5th, 2026
Oil Price Surge Sinks Stocks-Market Analysis: March 5th, 2026
Zacks Investment Research
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
Newswire.ca
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
Motley Fool
2 Top Defensive ETFs That Prioritize Stability Over Excitement
Zacks Investment Research
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
Zacks Investment Research
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Motley Fool
How to Spot Winning Innovation
Zacks Investment Research
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
Motley Fool
Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?
Zacks Investment Research
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
Motley Fool
2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash
Tipranks
DBS Remains a Hold on Johnson & Johnson (JNJ)
Zacks Investment Research
Can J&J Sustain Its Double-Digit Oncology Growth Streak?
Can J&J Sustain Its Double-Digit Oncology Growth Streak?
Motley Fool
ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock
Zacks Investment Research
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
Motley Fool
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio
Motley Fool
The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson
Zacks Investment Research
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
Zacks Investment Research
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
Zacks Investment Research
AbbVie Down Since Q4 Earnings Report: How to Play the Stock
AbbVie Down Since Q4 Earnings Report: How to Play the Stock
GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Zacks Investment Research
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
Zacks Investment Research
Should You Buy ISRG Stock Despite a 13% Fall in Three Months?
Should You Buy ISRG Stock Despite a 13% Fall in Three Months?
Zacks Investment Research
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?
Motley Fool
Is Johnson & Johnson a Buy, Sell, or Hold in 2026?
Zacks Investment Research
Here's What Will Drive AbbVie's Top-line Growth in 2026
Here's What Will Drive AbbVie's Top-line Growth in 2026
Newswire.ca
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

Profile

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.